121 related articles for article (PubMed ID: 31118678)
1. Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy.
Navari RM; Mosier MC
Onco Targets Ther; 2019; 12():3277-3284. PubMed ID: 31118678
[No Abstract] [Full Text] [Related]
2. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Navari RM
Expert Opin Drug Saf; 2020 Feb; 19(2):205-210. PubMed ID: 31709853
[No Abstract] [Full Text] [Related]
3. HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2019 Mar; 15(8):865-874. PubMed ID: 30574797
[TBL] [Abstract][Full Text] [Related]
4. Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review.
Walton GD
Adv Ther; 2019 Mar; 36(3):662-669. PubMed ID: 30706408
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
Ottoboni T; Keller MR; Cravets M; Clendeninn N; Quart B
Drug Des Devel Ther; 2018; 12():429-435. PubMed ID: 29535504
[TBL] [Abstract][Full Text] [Related]
6. Safety of antiemetic prophylaxis with HTX-019 as a 30-min infusion in patients with cancer: a retrospective study.
Perry TS; Dickson N; Patton JF
Future Oncol; 2020 Mar; 16(7):263-268. PubMed ID: 31984777
[No Abstract] [Full Text] [Related]
7. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2018 Nov; 14(27):2849-2859. PubMed ID: 29873529
[TBL] [Abstract][Full Text] [Related]
8. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
Navari RM
Future Oncol; 2019 Jan; 15(3):241-255. PubMed ID: 30304952
[TBL] [Abstract][Full Text] [Related]
9. Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis.
Calcanes G; Vacirca JL
J Infus Nurs; 2019; 42(5):260-263. PubMed ID: 31464835
[TBL] [Abstract][Full Text] [Related]
10. Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens.
Hingmire S; Raut N
South Asian J Cancer; 2015; 4(1):7-10. PubMed ID: 25839011
[TBL] [Abstract][Full Text] [Related]
11. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting.
Deeks ED
Drugs; 2016 Dec; 76(18):1779-1786. PubMed ID: 27915445
[TBL] [Abstract][Full Text] [Related]
12. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
[TBL] [Abstract][Full Text] [Related]
13. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
Karthaus M; Tibor C; Lorusso V; Singh-Arora R; Filippov A; Rizzi G; Borroni ME; Rossi G; Grunberg SM
Support Care Cancer; 2015 Oct; 23(10):2917-23. PubMed ID: 25724407
[TBL] [Abstract][Full Text] [Related]
17. Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting.
Navari RM; Schwartzberg LS
Onco Targets Ther; 2018; 11():6459-6478. PubMed ID: 30323622
[TBL] [Abstract][Full Text] [Related]
18. Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy.
Celio L; Niger M; Ricchini F; Agustoni F
Core Evid; 2015; 10():75-87. PubMed ID: 26345982
[TBL] [Abstract][Full Text] [Related]
19. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.
Dando TM; Perry CM
Drugs; 2004; 64(7):777-94. PubMed ID: 15025555
[TBL] [Abstract][Full Text] [Related]
20. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
